{
    "Trade/Device Name(s)": [
        "Access EPO",
        "Access EPO Reagent on DxI 9000 Access Immunoassay Analyzer"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240182",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052223"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGT"
    ],
    "Summary Letter Date": "April 22, 2024",
    "Summary Letter Received Date": "January 23, 2024",
    "Submission Date": "January 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 864.7250"
    ],
    "Regulation Name(s)": [
        "Erythropoietin assay"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "Erythropoietin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Two-site immunoenzymatic (sandwich) assay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Access EPO chemiluminescent immunoassay to quantitatively determine erythropoietin in serum and plasma on DxI 9000 Access Immunoassay Analyzer",
    "Indications for Use Summary": "Quantitative determination of erythropoietin levels in human serum and plasma (heparin) as an aid in the diagnosis of anemias and polycythemias using the Access Immunoassay Systems.",
    "fda_folder": "Hematology"
}